A new cancer vaccine is offering real hope against two of the most deadly and difficult-to-treat cancers: pancreatic and colorectal cancer.
The experimental vaccine, called ELI-002 2P, is designed to prevent these cancers from returning after surgery—something current treatments rarely achieve long-term.
In an early clinical trial with 25 patients who had just undergone surgery, the results were striking:
• 84% developed strong immune responses against cancer cells carrying the KRAS mutation, a genetic driver of most pancreatic cancers and nearly half of colorectal cancers.
• 24% had no remaining signs of cancer after treatment.
• Many patients who responded well remained cancer-free nearly 20 months later.
On average, patients had over 16 months before relapse and nearly 29 months survival—far better than typical outcomes for these aggressive cancers.
What makes this breakthrough especially promising is that the vaccine is “off-the-shelf,” meaning it doesn’t need to be custom-made for each patient, making it faster and more accessible to produce.
If larger trials confirm these findings, this could mark a major step forward in cancer prevention and long-term survival.
🔬 Source: J. Perkins, The Hill (2025)
#CancerResearch #MedicalBreakthrough #PancreaticCancer #ColorectalCancer #CancerVaccine #KRAS #Immunotherapy #Oncology #HealthNews
